SCHEMBL981130

SCHEMBL981130

CC(=O)Nc1ccc(C2(Cc3ccccc3)CCN(Cc3ccccc3)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.53
OPRD1 P41143 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
NPC1 O15118 1/20 0.51
NR3C1 P04150 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP2D6 P10635 3/20 0.46
CYP3A4 P08684 1/20 0.46
BACE1 P56817 1/20 0.46
PTPN1 P18031 1/20 0.46
GRIN2B Q13224 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981298 0.84 NR3C1 (0.48) OPRM1KMT2AKDM4ENR3C1TSHR
SCHEMBL20492967 0.83 OPRM1 (0.68) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL25053634 0.81 OPRM1 (0.58) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL20492994 0.81 MEN1 (0.53) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL20492863 0.78 OPRM1 (0.62) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL20493588 0.78 OPRM1 (0.57) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL20492796 0.78 OPRM1 (0.57) OPRM1OPRD1MEN1KMT2AL3MBTL1
SCHEMBL984578 0.77 NR3C1 (0.51) OPRM1MEN1KMT2AKDM4EALDH1A1
SCHEMBL981295 0.76 NR3C1 (0.50) OPRM1MEN1KMT2AKDM4EALDH1A1
SCHEMBL982937 0.76 SLC6A2 (0.54) KMT2ANPC1NR3C1HSD17B10CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 OPRM1 203/4885OPRD1 118/4885MEN1 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.